Tempus AI: Revolutionizing Healthcare with Artificial Intelligence
In the complex landscape of modern medicine, the journey from diagnosis to treatment can often be a winding path, fraught with uncertainties and generalized approaches. I’ve seen firsthand how fragmented information and a lack of personalized insights can impact patient care. This is the very challenge a company like Tempus AI aims to address, leveraging artificial intelligence to bring a new level of precision to healthcare.
Source: Own illustration
Tempus AI, a technology company headquartered in Chicago, Illinois, USA, focuses on advancing precision medicine by applying artificial intelligence in healthcare. Founded in 2015 by Eric Lefkofsky, the company emerged from his personal experience observing the insufficient integration of technology in his wife's breast cancer treatment. Today, Tempus AI operates with a workforce of approximately 2,300 employees and is publicly traded on Nasdaq under the ticker symbol TEM. Its core mission involves utilizing one of the world's largest libraries of clinical and molecular data to empower physicians with real-time, data-driven decisions and enhance personalized patient care, as detailed on Tempus AI’s official website.
Source: chicagomag.com
Eric Lefkofsky, the visionary behind Tempus AI, launched the company in 2015 after seeing firsthand the need for better technology integration in his wife’s breast cancer treatment.
Quick Summary: What Tempus AI Does
Tempus AI is at the forefront of precision medicine, utilizing AI to transform healthcare. Here’s a quick overview of their key activities:
- Data-Driven Decisions: Employs one of the world’s largest libraries of clinical and molecular data to provide real-time, data-driven insights for physicians.
- Personalized Patient Care: Enhances individualized treatment strategies across various medical fields, especially oncology.
- Three Core Pillars: Operates through Genomics (testing services), Data & Services (licensing data to pharma), and Apps (AI-powered tools for healthcare professionals and patients).
- Strategic Acquisitions: Continuously expands capabilities through targeted acquisitions of companies specializing in clinical trials, genetic testing, and AI-driven recruitment.
- Market Leader: Holds a strong position in comprehensive genomic profiling and is poised for growth in liquid biopsy methods.
Tempus AI’s Core Business Model: Genomics, Data, and Apps
Tempus AI’s business model is structured around three primary product lines: Genomics, Data, and Apps. Each segment contributes to its overarching goal of integrating AI into precision medicine.
Genomics Sector
The Genomics sector generates revenue through genomic and diagnostic testing services. While primarily focused on oncology, these services also extend to cardiology, radiology, and pharmacogenomics for patients with depression. Tempus AI operates CAP-accredited and CLIA-certified laboratories for high-throughput genome sequencing. For example, the Tempus xT platform has been shown to increase personalized therapeutic opportunities for cancer patients, a finding published in Nature Biotechnology. The company also actively validates liquid biopsy assays, which profile circulating tumor DNA, for advanced molecular and clinical insights, as discussed in their validation study. In January 2025, Tempus AI announced the national launch of its FDA-approved xT CDx Test.
Source: tempus.com
The Tempus xT platform has demonstrated its effectiveness in increasing personalized therapeutic options for cancer patients, as noted in a Nature Biotechnology publication.
Data & Services Division
The Data & Services division is responsible for licensing de-identified clinical and molecular data, along with analytical tools, to pharmaceutical and biotech companies. This data supports research, drug development, and clinical trials. Tempus AI collaborates with over 95% of the top-20 pharmaceutical oncology companies and more than 250 biopharma partners. Their library contains over 8 million de-identified research datasets and manages over 350 petabytes of data, as highlighted on their LinkedIn page. Strategic collaborations, such as the one with AstraZeneca, aim to advance oncology therapeutics through data licensing, a partnership announced in this press release.
Apps Area
The Apps area features a suite of AI-powered products designed to assist healthcare providers, researchers, and patients. These include:
- Tempus Hub: A secure platform optimizing workflows and providing patient insights.
- Tempus Lens: An analytics platform for rapid access and analysis of multi-modal data to accelerate innovation.
- Tempus Next: An AI-powered care pathway platform guiding providers on subsequent steps in patient care.
- Tempus One: An AI-powered assistant for healthcare providers and researchers, launched in 2023, with new generative AI features (including a patient timeline) introduced in January 2025.
- Tempus Link: Software facilitating clinical trial matching and enrollment.
- Olivia: An AI-powered personal health concierge app for patients, launched nationally in January 2025, to consolidate health data and provide actionable insights.
Tempus AI also received U.S. FDA 510(k) clearance for its Tempus ECG-Low EF Software, which uses AI to identify patients with low left ventricular ejection fraction (LVEF).
Source: unknown
Tempus AI received U.S. FDA 510(k) clearance for its Tempus ECG-Low EF Software, which leverages AI to identify patients with low left ventricular ejection fraction (LVEF).
Expanding Reach Through Strategic Acquisitions
Tempus AI has strategically expanded its capabilities through various acquisitions, bolstering its position in clinical trials, genetic testing, and AI-driven healthcare solutions.
| Acquisition Date | Acquired Company | Purpose | Source |
|---|---|---|---|
| February 2022 | Highline Sciences | Strengthen support for AI-enabled clinical trials. | Press Release |
| September 2023 | Mpirik | Enhance cardiovascular care through AI for early detection. | Announcement |
| February 2025 (completed) | Ambry Genetics | Expand genetic testing capabilities ($600M cash and stock). | News Release |
| March 2025 | Deep 6 AI | Bolster AI-driven clinical trial recruitment with a vast patient network. | Investor News Release |
These acquisitions, alongside developing organoid platforms for precision medicine, as detailed in their publications, underscore Tempus AI’s growth strategy.
Growth and Market Position of Tempus AI
Tempus AI has demonstrated significant revenue growth, reporting $188 million in 2020, $258 million in 2021, $321 million in 2022, and $532 million in 2023, representing a 65.8% year-over-year increase. For the full year 2024, revenue reached $693.4 million, a 30% increase from 2023, according to a Tempus AI news report. The company's gross margin has also improved, rising from approximately 41% in 2020 to about 55% in 2024. Tempus AI aims to achieve adjusted EBITDA profitability in 2025.
The company holds a strong market position in tissue-based comprehensive genomic profiling (CGP) with its xT test and is positioned to benefit from the increasing adoption of liquid biopsy methods with its xM test, as analyzed by Seeking Alpha. Over 65% of U.S. academic medical centers and more than 50% of U.S. oncologists are connected with Tempus AI through sequencing, clinical trial matching, and research partnerships. The company has identified over 40,000 patients for potential clinical trial participation within its network. Analysts view the market for AI-powered health data services and precision oncology diagnostics as attractive, with an addressable market exceeding $40 billion and growth rates of over 30 percent, as reported by TradingView.
Frequently Asked Questions about Tempus AI
Who founded Tempus AI and why?
Tempus AI was founded in 2015 by Eric Lefkofsky. He was motivated by his personal experience during his wife’s breast cancer treatment, where he observed a significant lack of integrated technology and personalized data in her care.
What types of data does Tempus AI use?
Tempus AI utilizes one of the world’s largest libraries of clinical and molecular data. This includes de-identified patient data, genomic sequencing results, and other health information, which amounts to over 8 million research datasets and more than 350 petabytes of data.
How does Tempus AI help cancer patients?
Tempus AI helps cancer patients through its Genomics sector by offering advanced genomic and diagnostic testing services, such as the xT platform, which identifies personalized therapeutic opportunities. They also facilitate clinical trial matching and provide AI-powered tools for oncologists to make data-driven decisions.
Is Tempus AI publicly traded?
Yes, Tempus AI is publicly traded on Nasdaq under the ticker symbol TEM.
What is Tempus One?
Tempus One is an AI-powered assistant designed for healthcare providers and researchers. It provides rapid insights and uses generative AI to query unstructured data, helping professionals access critical patient information and research findings more efficiently. New generative AI features, including a patient timeline, were introduced in January 2025.
Conclusion
Tempus AI is not just a technology company; it represents a significant shift in how medicine can be practiced. By harnessing vast amounts of data and advanced AI, it empowers healthcare professionals with the insights needed to deliver personalized and precise care. Its continuous innovations, from genomics to AI-powered applications, and strategic acquisitions, position Tempus AI at the forefront of transforming healthcare, ultimately aiming to improve patient outcomes on a global scale.
Source: YouTube